New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. In this review, the wide-ranging aspects of the evolution of EGFR-TKIs were collected, with a special focus on rociletinib. The influence of different oncoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Der Steen, Nele, Caparello, Chiara, Rolfo, Christian, Pauwels, Patrick, Peters, Godefridus J, Giovannetti, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063481/
https://www.ncbi.nlm.nih.gov/pubmed/27785053
http://dx.doi.org/10.2147/OTT.S97644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063481/
https://www.ncbi.nlm.nih.gov/pubmed/27785053
http://dx.doi.org/10.2147/OTT.S97644

Ejemplares similares